Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Payables (2020 - 2025)

Historic Payables for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $103.5 million.

  • Tarsus Pharmaceuticals' Payables rose 8975.49% to $103.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.5 million, marking a year-over-year increase of 8975.49%. This contributed to the annual value of $64.8 million for FY2024, which is 17347.52% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Payables stood at $103.5 million for Q3 2025, which was up 8975.49% from $78.6 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Payables' 5-year high stood at $103.5 million during Q3 2025, with a 5-year trough of $8.1 million in Q3 2021.
  • Over the past 5 years, Tarsus Pharmaceuticals' median Payables value was $10.8 million (recorded in 2022), while the average stood at $31.1 million.
  • Its Payables has fluctuated over the past 5 years, first crashed by 1625.17% in 2023, then soared by 36015.44% in 2024.
  • Tarsus Pharmaceuticals' Payables (Quarter) stood at $8.7 million in 2021, then increased by 14.17% to $9.9 million in 2022, then surged by 139.06% to $23.7 million in 2023, then soared by 173.48% to $64.8 million in 2024, then surged by 59.75% to $103.5 million in 2025.
  • Its last three reported values are $103.5 million in Q3 2025, $78.6 million for Q2 2025, and $76.4 million during Q1 2025.